Microencapsulated rBMMSCs/calcium phosphate cement for bone formation in vivo
Issue title: Frontiers in Biomedical Engineering and Biotechnology – Proceedings of the 2nd International Conference on Biomedical Engineering and Biotechnology, 11–13 October 2013, Wuhan, China
Affiliations: Peking University School and Hospital of Stomatology, 22 Zhong-Guan-Cun South Ave, Beijing, 100081, China | Beijing Key Lab of Fine Ceramics, Institute of Nuclear and New Energy Technology, Tsinghua University, Energy Science Building, Beijing, 100084, China
Abstract: As an injectable scaffold material for bone tissue engineering, calcium phosphate cement (CPC) has good biocompatibility, self-setting, and osteoconduction properties. Alginate-microencapsulated seed cells can pick up the degradation speed and bioactivity of CPC. The aim of this study was to explore the osteogenic ability of a composite of microencapsulated rabbit bone marrow mesenchymal stem cells (rBMMSCs) with β-tricalcium phosphate/calcium phosphate cement (β-TCP/CPC) in vivo. Cavity defects were created in both femoral condylar regions of New Zealand White rabbits. β-TCP/CPC (control group) and alginate microencapsulated rBMMSCs/β-TCP/CPC composite (composite group) were implanted separately into the bone defects of both femurs. Bone substitute degradation and new bone formation were evaluated by CBCT, and the defects were examined histologically 8, 16, and 24 weeks after implantation. In addition, fluorescent carbocyanine CM-Dil was used to track the rBMMSCs in vivo after implantation. The results showed that far more new bone and bone marrow grew into the bone defects in the composite group. Few CM-Dil labeled positive cells were observed postoperatively. However more native cells were detected in the graft areas of the composite group than those of the control group. The study indicates that a composite of microencapsulated seed cells/β-TCP/CPC might be considered as a promising injectable material for the generation of new bone tissue.
